As part of Xenon's ongoing collaboration with Neurocrine Biosciences, a Phase 1 study is underway of NBI-921355, an investigational, selective inhibitor of voltage-gated sodium channels Nav1.2 and ...

Epilepsy, one of the most common neurological disorders characterized by recurrent seizures, affects over 70 million people worldwide.

Epilepsy, one of the most common neurological disorders characterized by recurrent seizures, affects over 70 million people worldwide. In the United States, about 3.4 million people live with this ...

Epilepsy, one of the most common neurological disorders characterized by recurrent seizures, affects over 70 million ...

In the third quarter of 2025, the Company expects to present data from its ongoing Phase I/II studies of AMT-130 in support of a potential BLA submission. The update will include follow-up data on all ...

Chardan initiates Bright Minds with a Buy rating, citing over $1 billion sales potential for epilepsy drug BMB-101 despite ...

Chardan initiates Praxis with a Buy rating, highlighting its epilepsy pipeline, strong cash position, and billion-dollar ...

Treatment with cenobamate may reduce seizure frequency among patients with drug-resistant epilepsy after 3 months.

Incoming Syracuse women's basketball freshman Justus Fitzgerald smiles on her last day staying in the intensive care unit of ...